Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629-Reference-Cited by-同舟云学术

Health-Related Quality of Life of Patients with Recurrent or Metastatic Cutaneous Squamous Cell Carcinoma Treated with Pembrolizumab in KEYNOTE-629

Published:2021-09-23 Issue:5 Volume:11 Page:1777-1790
ISSN:2193-8210
Container-title:Dermatology and Therapy
language:en
Short-container-title:Dermatol Ther (Heidelb)

Author:

Hughes Brett G. M.^ORCID,Mendoza Rene Gonzalez,Basset-Seguin Nicole,Vornicova Olga,Schachter Jacob,Joshi Abhishek,Meyer Nicolas,Grange Florent,Piulats Josep M.,Bauman Jessica R.,Chirovsky Diana,Zhang Pingye,Gumuscu Burak,Swaby Ramona F.,Grob Jean-Jacques

Funder

Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA

Publisher

Springer Science and Business Media LLC

Subject

Dermatology

Link

https://link.springer.com/content/pdf/10.1007/s13555-021-00598-6.pdf

Reference31 articles.

1. Burton KA, Ashack KA, Khachemoune A. Cutaneous squamous cell carcinoma: a review of high-risk and metastatic disease. Am J Clin Dermatol. 2016;17(5):491–508.

2. Rogers HW, Weinstock MA, Feldman SR, Coldiron BM. Incidence estimate of nonmelanoma skin cancer (keratinocyte carcinomas) in the US population, 2012. JAMA Dermatol. 2015;151(10):1081–6.

3. Garcovich S, Colloca G, Sollena P, et al. Skin cancer epidemics in the elderly as an emerging issue in geriatric oncology. Aging Dis. 2017;8(5):643–61.